Quick Answer
The FDA accepted Sandoz applications for generic tirzepatide (the active ingredient in Mounjaro and Zepbound) on June 29, 2026. Generic versions could cost $200-400/month vs $1,000+ for branded. Indian patients may get access sooner as tirzepatide patents expire earlier outside the US.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The U.S. Food and Drug Administration has officially accepted applications from Swiss pharmaceutical company Sandoz to review generic versions of Mounjaro and Zepbound — two of the most powerful weight-loss and diabetes drugs on the market. The announcement, made on June 29, 2026, marks the first time the global regulatory machinery has formally opened the door to generic tirzepatide, the active ingredient in both drugs. For Indian patients who have been waiting for more affordable access to this class of medication, the news is significant — and the timeline for India could be far shorter than for the United States.
What Happened
Sandoz, one of the world largest generic pharmaceutical manufacturers, filed applications with the FDA to develop generic versions of both Mounjaro (approved for type 2 diabetes) and Zepbound (approved for obesity and sleep apnea). The FDA agreed to formally review these applications — an important regulatory milestone that signals the process has begun. Sandoz has estimated that its generic tirzepatide products would cost between $200 and $400 per month without insurance, compared to more than $1,000 per month for the branded versions made by Eli Lilly. The applications cover the same uses as the brand-name drugs: weekly subcutaneous injections for managing blood sugar in type 2 diabetes and for treating obesity.
The Patent Problem in the United States
Here is the catch: Eli Lilly holds patents on Mounjaro and Zepbound in the United States that do not expire until 2036. Under US law, generic versions cannot be sold until those patents expire, unless a court grants an exception or a compulsory licence is issued. This means that even if the FDA approves the Sandoz applications — which typically takes around 10 months — the drugs cannot actually reach American pharmacy shelves unless there is a successful patent challenge or a settlement. Experts are cautious about the US timeline.
However — and this is the key point for Indian patients — the patent situation outside the United States is entirely different.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Why India Could Get Generic Tirzepatide Much Sooner
India has some of the most robust compulsory licensing provisions in the world under its patent law. The Indian Patents Act includes Section 84, which allows the Indian government to grant a compulsory licence for a drug if it is not available to the public at a reasonably affordable price. Beyond that, Eli Lilly tirzepatide patents in many non-US jurisdictions expire well before 2036. In markets where the patents have already expired, generic manufacturing can begin immediately.
Generic semaglutide — the active ingredient in Ozempic and Wegovy — is a useful precedent. In India, when the patent on semaglutide expired in early 2026, domestic manufacturers including Natco Pharma and Cipla moved quickly to launch generic versions at prices as low as Rs 1,290 per month, compared to Rs 12,000 to Rs 18,000 per month for branded Ozempic. The market transformation was rapid and dramatic. If the same pattern follows for tirzepatide, Indian patients could gain access to a significantly more powerful weight-loss drug at a fraction of its current cost.
Canada has already moved ahead: in June 2026, Health Canada approved Sevian, a generic version of semaglutide for weight loss manufactured by Apotex. The global generic GLP-1 wave is building fast.
Why Does Tirzepatide Matter More Than Semaglutide?
Tirzepatide is a dual-agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces meaningfully greater weight loss than semaglutide alone. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine, showed that tirzepatide produced approximately 20 percent body weight reduction versus around 14 percent for semaglutide over 72 weeks. In practical terms, this means that a person weighing 100 kg could expect to lose approximately 20 kg on tirzepatide versus 14 kg on semaglutide — a clinically significant difference.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
At current Indian prices, branded Mounjaro costs Rs 20,000 to Rs 35,000 per month — far out of reach for most patients. If generic tirzepatide follows the same pricing trajectory as generic semaglutide in India, prices could fall to Rs 2,000 to Rs 5,000 per month within 12 to 24 months of patent expiry. At those price points, tirzepatide would become genuinely accessible to a large segment of the 77 million Indians living with type 2 diabetes and the hundreds of millions more at risk of obesity-related complications.
What Indian Patients Should Do Now
If you are currently on semaglutide and wondering whether to switch to tirzepatide, the answer depends on your individual clinical situation — how much weight you have lost so far, your blood sugar control, any side effects you have experienced, and your budget. Generic tirzepatide is not yet available in India, but branded Mounjaro is, and the cost may come down as the generic market develops globally.
If you have not yet started GLP-1 therapy, generic semaglutide is available today at prices starting from Rs 1,290 per month and is a strong first choice for most patients. A GLP-1 specialist can help you understand which option is right for your situation and prepare you for the significantly more powerful options that are coming as the market matures.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Healthline — Generic Mounjaro, Zepbound May Be Coming, Rivaling Current GLP-1s — https://www.healthline.com/health-news/generic-mounjaro-zepbound-application-review 2. Drug Topics — FDA Accepts Sandoz Applications for Generic Tirzepatide — https://www.drugtopics.com/view/fda-accepts-sandoz-applications-for-generic-tirzepatide 3. New England Journal of Medicine — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.